Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from DXCM

DexCom's Q4 2025 Earnings: What to Expect

DexCom will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Is DexCom Stock Underperforming the S&P 500?

Is DexCom Stock Underperforming the S&P 500?

DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects.

DexCom Stock: Is Wall Street Bullish or Bearish?

DexCom Stock: Is Wall Street Bullish or Bearish?

Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL Education Inc (NYSE:TAL), Shake Shack Inc (NYSE:SHAK) and DexCom Inc (NASDAQ:DXCM).

DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor

DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.

DexCom Earnings Preview: What to Expect

DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.

Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.

inkl

Read news from The Economist, FT, and more,
with one subscription

Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside

Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside

These two companies could present an opportunity for investors to gain access while they are relatively undervalued and before they appreciate once again.

How Is DexCom's Performance Compared to Other Medical Device Companies?

How Is DexCom's Performance Compared to Other Medical Device Companies?

DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.

DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy

DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy

Wall Street gives these three diverse names Strong Buy recommendations with high potential upside.

What You Need to Know Ahead of DexCom’s Earnings Release

What You Need to Know Ahead of DexCom’s Earnings Release

DexCom is all geared up to announce its second-quarter earnings towards the end of this month, and analysts anticipate a single-digit bottom-line growth.

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love

Policies associated with the MAHA movement could boost these two stocks significantly.

DexCom Stock: Is DXCM Underperforming the Health Care Sector?

DexCom Stock: Is DXCM Underperforming the Health Care Sector?

DexCom has underperformed the Health Care sector over the past year, but analysts are highly optimistic about the stock’s prospects.

What to Expect From DexCom's Next Quarterly Earnings Report

What to Expect From DexCom's Next Quarterly Earnings Report

DexCom will release its first-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Get all your
news in one place.

100’s of premium titles.
One news app.

Is DexCom Stock Underperforming the Dow?

DexCom significantly underperformed the Dow over the past year, yet analysts remain strongly bullish on the stock’s long term prospects.

DexCom Stock Outlook: Is Wall Street Bullish or Bearish?

Although DexCom has significantly lagged behind the broader market over the past year, Wall Street analysts remain strongly optimistic about the stock's prospects.

What to Expect From DexCom's Q4 2024 Earnings Report

DexCom is gearing up to release its fourth-quarter earnings next month, and analysts forecast single-digit profit growth.

Is DexCom Stock Underperforming the Nasdaq?

Despite DexCom's lagging performance relative to the Nasdaq Composite over the past year, Wall Street analysts maintain a strong bullish outlook on the stock's prospects.

Get all your
news in one place.

100’s of premium titles.
One news app.

Are Wall Street Analysts Predicting DexCom Stock Will Climb or Sink?

Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Here's What to Expect From DexCom's Next Earnings Report

DexCom is poised to announce its third-quarter results later this month, with analysts predicting a double-digit decline in the company's earnings.

Is DexCom Stock Underperforming the S&P 500?

Despite DexCom’s underperformance compared to the S&P 500 Index over the past year, Wall Street analysts are highly bullish about the stock’s prospects.

Is Wall Street Bullish or Bearish on DexCom Stock?

Despite DexCom lagging behind the broader market over the past year, Wall Street analysts remain bullish on the stock’s prospects.

Dexcom Stock Sinks on Sales Miss, Guidance Cut: What to Know

Dexcom stock is crashing Friday after the glucose monitoring company reported dismal Q2 revenue and slashed its full-year sales guidance. Here's what you need to know.

3 Top-Rated Healthcare Stocks With 20% to 35% Upside Potential

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

Earnings Preview: What to Expect From DexCom's Report

DexCom is gearing up to announce its second-quarter results this month, and analysts are anticipating a double-digit increase in the company’s bottom-line figure.

People

Robert F. Kennedy Jr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Food and Drug Administration

Abbott Laboratories

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

338,434 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play